IP Library › Granted Patent US 12,590,131
Granted Patent B2
US 12,590,131 · App. 18/636,117 · Granted Mar 31, 2026

Antimicrobial peptides with alpha-core helices

Inventors: Nannette Y. Yount (San Juan Capistrano, CA); Michael R. Yeaman (Redondo Beach, CA)
Assignee: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
C07K14/4723C07K14/43518C07K14/43522C07K14/43568C07K14/43572C07K14/43581C07K14/463C07K14/465G16B15/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,131
App. No.
18/636,117
Granted
Mar 31, 2026
Kind
B2
Abstract

Computational systems and methods are described for identifying new α-helical antimicrobial peptides using a systemic consensus formula. Newly identified α-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

Claims (8)

1 . A method for treating an infection in a patient in need thereof, comprising administering to the patient a peptide comprising the amino acid sequence of SEQ ID NO:1, wherein the peptide is not longer than 60 amino acid residues in length.

2 . The method of claim 1 , wherein the peptide is not longer than 50 amino acid residues in length.

3 . The method of claim 1 , further comprising administering to the patient an antimicrobial agent.

4 . The method of claim 3 , wherein the antimicrobial agent is selected from the group consisting of imipenem, ceftazidime, colistin, chloroquine, artemisinin, vancomycin and daptomycin.

5 . The method of claim 1 , wherein the infection is caused by a Gram-negative bacterium, a Gram-positive bacterium or a fungus.

6 . The method of claim 1 , wherein the administration is subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, or intracranial injection, or infusion.

7 . The method of claim 1 , wherein the patient is a mammal.

8 . The method of claim 7 , wherein the patient is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2025
From: YOUNT, NANNETTE; YEAMAN, MICHAEL R.
To: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 070500/0275 →
CHANGE OF NAME Recorded Mar 13, 2025
From: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
To: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
Reel/Frame 070500/0713 →
Continuity (4)
Continuation 18053981 · Nov 9, 2022
Division 16612242
Provisional Application 62505013 · May 11, 2017
Related Publication 20240279292A1 · Aug 22, 2024
References Cited (27)
US 5607914A · Rao et al. · 1997 [cited by applicant]
US 7739055B2 · Stephanopoulos et al. · 2010 [cited by applicant]
US 7807876B1 · Navarro et al. · 2010 [cited by applicant]
US 9133257B2 · Yeaman et al. · 2015 [cited by applicant]
US 20100076173A1 · Stephanopoulos et al. · 2010 [cited by applicant]
US 20150232521A1 · Yeaman et al. · 2015 [cited by applicant]
US 20170121384A1 · Yount et al. · 2017 [cited by applicant]
KR 20030061718 · 2003 [cited by applicant]
WO WO2016197049 · 2016 [cited by applicant]
WO WO2017048092 · 2017 [cited by applicant]
Saumya, Donna et al, “Acute septicemia caused by [cited by examiner]
Linch, Stefanie N. et al, “Interleukin 5 is protective during sepsis in an eosinophil independent manner.” Am. J. Respir. Crit. Care Med. (2012) 186(3) p. 246-254. [cited by examiner]
Uniprot database entry GINOU6, downloaded Apr. 3, 2025. [cited by examiner]
Novelli, Andrea et al, “Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.” Clin. Pharmacokinet. (2006) 44(5) p. 539-549. [cited by examiner]
Takatsu, Kiyoshi, “Interleukin-5 and il-5 receptor in health and disease.” Proc. Jpn. Acad. Ser. B (2011) 87(8) p. 463-485. [cited by examiner]
Lowe, Derek, “Not alphafold's fault.” blog “In the pipeline” entry of Sep. 7, 2022. [cited by examiner]
Guo, Haiwei H. et al, “Protein tolerance to random amino acid change.” PNAS (2004) 101(25) p. 9205-9210. [cited by examiner]
Yampolsky, Lev Y. et al, “THe exchangeability of amino acids in proteins.” Genetics (2006) 170 p. 1459-1472. [cited by examiner]
Database UniProt [online] Accession No. G1 N9U6, “RecName: Full=Interleukin-5 {ECO:0000256: RuleBase: RU363136}; AltName: Full=Eosinophil differentiation factor {ECO:0000256: RuleBase:RU363136},” Oct. 19, 2011. [cited by applicant]
Database Geneseq [online] Accession No. AAP60411, “Exon 4 of human interferon-gamma,” Mar. 25, 2003. [cited by applicant]
Database UniProt [online] Accession No. W2G110, “SubName: Full=Uncharacterized protein {ECO:0000313: Embl: ETK76743.1},” Mar. 19, 2014. [cited by applicant]
Database UniProt [online] Accession No. W2Y3P7, “SubName: Full=Uncharacterized protein {ECO:0000313: EMBL: ETP29352.1},” Mar. 19, 2014. [cited by applicant]
Database Geneseq [online] Accession No. AAM05438, “Peptide #4120 encoded by probe for measuring breast gene Expression,” Oct. 9, 2001. [cited by applicant]
Database UniProt [online] Accession No. W2Z9T6, “SubName: Full=Uncharacterized protein ECO:0000313IEMBL:ETP42979.1},” Mar. 19, 2014. [cited by applicant]
Database UniProt [online] Accession No. A0A081A496, “SubName: Full=Uncharacterized protein ECO:0000313IEMBL:ETO73707.1},” Oct. 29, 2014. [cited by applicant]
Bairoch et al., “The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000”, Nucleic Acids Res, Jan. 1, 2000, vol. 28, No. 1, pp. 45-48. [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/032133 dated Oct. 18, 2018, 15 pages. [cited by applicant]